Featured Research

from universities, journals, and other organizations

Drug Candidate Slows Age-related Macular Degeneration

Date:
October 18, 2008
Source:
Case Western Reserve University
Summary:
Research results show that the progression of age-related macular degeneration is markedly slowed in new laboratory-engineered mice when they received treatments of retinylamine, a trial drug that has been tested in a medical school lab. AMD is a leading cause of vision loss in Americans 60 years of age and older.

Research results from the Case Western Reserve University School of Medicine show that the progression of age-related macular degeneration (AMD) is markedly slowed in new laboratory-engineered mice when they received treatments of retinylamine, a trial drug that has been tested in a medical school lab. AMD is a leading cause of vision loss in Americans 60 years of age and older.

The findings from the National Eye Institute-funded research are reported in the Journal of Biological Chemistry.

Led by postdoctoral researcher Akiko Maeda, an investigator in the lab of one of her co-authors, Krzysztof Palczewski, the findings provide evidence for biochemical change in the retina that resemble AMD. Palczewski is chair and the John H. Hord Professor of Pharmacology at the School of Medicine. While the drug itself was developed in Palczewski's former lab at the University of Washington, it was brought to Case Western Reserve when he and his team of researchers, including Maeda, arrived here in 2005.

Palczewski says AMD currently isn't usually treated until toward the end of the disease. However, with the discovery in his lab by Maeda and her research team, retinylamine can potentially prevent the rapid degeneration of the eye, slowing the rate of progression of AMD.

As humans go through the aging process, it eventually affects our vision. A fraction of us will progress further and potentially develop AMD. Through their work on mouse models, Maeda and her team of researchers have learned to modify the genes that establish the rate of changes related to AMD. But the biochemical trigger of these changes had not been understood until now as a result of the retinylamine treatments.

"We have proven this observation, genetically, biochemically and pharmacologically," Palczewski said. "Dr. Maeda, who studies retinal degenerative diseases in my lab and works to develop models that will facilitate the evaluation of the safety and effectiveness of drug candidates designed to combat retinal disease in humans, has done superb work in this area. We're very excited about the potential this outcome represents."

AMD is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. AMD causes no pain.

In some cases, AMD advances so slowly that people notice little change in their vision. In others, the disease progresses faster and may lead to a loss of vision in both eyes. An estimated 8 million older-age Americans are at high risk to develop advanced AMD. Of these 8 million, 1.3 million would develop advanced AMD within five years.

"Until now, with the discovery in our lab, the genesis of that progression wasn't known," Palczewski said. "Now we have the potential to intervene in the middle of the disease's advancement so we can prevent rapid degeneration of the eye. The importance of this work also is illustrated by the five-year K08 award made to Dr. Maeda by the National Eye Institute."

The National Institutes of Health's K08 award provides support and "protected time" for an intensive, supervised research career development experience in the fields of biomedical or behavioral research, including translational research. The K08 award supports a three, four, or five year period of supervised research experience.


Story Source:

The above story is based on materials provided by Case Western Reserve University. Note: Materials may be edited for content and length.


Cite This Page:

Case Western Reserve University. "Drug Candidate Slows Age-related Macular Degeneration." ScienceDaily. ScienceDaily, 18 October 2008. <www.sciencedaily.com/releases/2008/10/081009144107.htm>.
Case Western Reserve University. (2008, October 18). Drug Candidate Slows Age-related Macular Degeneration. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2008/10/081009144107.htm
Case Western Reserve University. "Drug Candidate Slows Age-related Macular Degeneration." ScienceDaily. www.sciencedaily.com/releases/2008/10/081009144107.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins